Palvella Therapeutics (PVLA) Non-Current Assets (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Non-Current Assets of $528000.0 for Q1 2026, down 7.69% quarter-over-quarter from $572000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Non-Current Assets (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Non-Current Assets for 13 consecutive years, with $528000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets changed N/A year-over-year to $528000.0; the TTM figure through Mar 2026 stood at $1.1 million (up 283.28% YoY), while the FY2025 annual figure was $572000.0, changed N/A from the prior year.
- Non-Current Assets slipped to $528000.0 in Q1 2026 per PVLA's latest filing, from $572000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $25.4 million in Q1 2022 and bottomed at $287000.0 in Q3 2023.
- Historically, Non-Current Assets has averaged $15.1 million across 4 years, with a median of $21.1 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets fell 7.81% — and 2023, when it slumped 98.61%.
- Palvella Therapeutics' Non-Current Assets stood at $22.1 million in 2022, then slumped by 98.7% to $287000.0 in 2023, then soared by 99.3% to $572000.0 in 2025, then slipped by 7.69% to $528000.0 in 2026.
- Business Quant data shows PVLA's Non-Current Assets at $528000.0 in Q1 2026, $572000.0 in Q4 2025, and $287000.0 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 482,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 482,000.00 |
| Mar 31, 2026 | 528,000.00 |
| Dec 31, 2025 | 572,000.00 |
| Sep 30, 2023 | 287,000.00 |
| Jun 30, 2023 | 21.07 Mn |
| Mar 31, 2023 | 21.75 Mn |
| Dec 31, 2022 | 22.07 Mn |
| Sep 30, 2022 | 20.60 Mn |
| Jun 30, 2022 | 23.41 Mn |
| Mar 31, 2022 | 25.37 Mn |
| Dec 31, 2021 | 25.94 Mn |
| Sep 30, 2021 | 26.54 Mn |
| Jun 30, 2021 | 27.36 Mn |
| Mar 31, 2021 | 27.51 Mn |
| Dec 31, 2020 | 29.29 Mn |
| Sep 30, 2020 | 27.07 Mn |
| Jun 30, 2020 | 25.76 Mn |
| Mar 31, 2020 | 25.40 Mn |
| Dec 31, 2019 | 26.08 Mn |
| Sep 30, 2019 | 18.78 Mn |